Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Activation in transformed cells of normal stem cells' self-renewal pathways might contribute to the survival life cycle of cancer stem cells and promote tumor progression. The BMI-1 oncogene-driven gene expression pathway is essential for the self-renewal of hematopoietic and neural stem cells. We applied a mouse/human comparative translational genomics approach to identify an 11-gene signature that consistently displays a stem cell-resembling expression profile in distant metastatic lesions as revealed by the analysis of metastases and primary tumors from a transgenic mouse model of prostate cancer and cancer patients. To further validate these results, we examined the prognostic power of the 11-gene signature in several independent therapy-outcome sets of clinical samples obtained from 1,153 cancer patients diagnosed with 11 different types of cancer, including 5 epithelial malignancies (prostate, breast, lung, ovarian, and bladder cancers) and 5 nonepithelial malignancies (lymphoma, mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia). Kaplan-Meier analysis demonstrated that a stem cell-like expression profile of the 11-gene signature in primary tumors is a consistent powerful predictor of a short interval to disease recurrence, distant metastasis, and death after therapy in cancer patients diagnosed with 11 distinct types of cancer. These data suggest the presence of a conserved BMI-1-driven pathway, which is similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a high probability of unfavorable therapy outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated expression of this signature is associated with cancer development and chemotherapy resistance in different types of cancer, including hematological malignancies.11”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 4×
“We therefore sought to investigate whether measurements of expression of the 11-gene MTTS/PNS signature would be informative in the prediction of the patients’ prognosis in a group of 97 young women diagnosed with sporadic lymph node– negative early-stage breast cancer who were analyzed in a recent expression profilin…”
BackgroundMethodInfluentialA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Systematic determination of genetic network architecture
Tavazoie, S., Hughes, J. D., Campbell, M. J., Cho, R. J., & Church, G. M. (1999) · Nature Genetics · doi:10.1038/10343 · Cited by 2,507 · cited 1×
“We calculated the significance of the overlap between the lists of stem cell–associated and prostate cancer–associated genes by using the hypergeometric distribution test (54).”
MethodA molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Cited by
Items 701–800 of 914
Investigational Approaches for Mesothelioma
Surmont, V. F. M., van Thiel, E. R. E., Vermaelen, K. Y., & van Meerbeeck, J. P. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00022 · Cited by 8
“lack of concordance between the various predictive or prognostic studies (Gordon et al., 2003, 2005a; Pass et al., 2004; Glinsky et al., 2005; Lopez-Rios et al., 2006) Nevertheless, several of the genes identified in these predictive array studies have also shown up in other MPM array studies.”
BackgroundResultYano, S., Takehara, K., Tazawa, H., Kishimoto, H., Kagawa, S., Bouvet, M., Fujiwara, T., & Hoffman, R. M. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25735 · Cited by 6
“Previously, we observed that major resection of the liver stimulated liver and lung metastatic growth along with recruitment of host-derived stroma compared with repeated minor resection [Glinsky et al., 2005].”
BackgroundPrognostic Value of FBXO39 and ETS-1 but not BMI-1 in Iranian Colorectal Cancer Patients
Motalebzadeh, J., Shabani, S., Rezayati, S., Shakournia, N., Mirzaei, R., Mahjoubi, B., Hoseini, K., & Mahjoubi, F. (2018) · PubMed Central · doi:10.22034/apjcp.2018.19.5.1357 · Cited by 8
“Asian Pacific Journal of Cancer Prevention, Vol 19 1358 as an oncogene in cell proliferation and cell movement (Jacobs et al., 1999; Glinsky et al., 2005).”
BackgroundWang, Y., Jia, Z., Gao, J., Zhou, T., Zhang, X., & Zu, G. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.920595 · Cited by 7
CD133 and BMI1 expressions and its prognostic role in primary glioblastoma
Sibin, M. K., Lavanya, C., Bhat, D. I., Rao, N., GEETHASHREE, N., VIBHUTI, W., & Chetan, G. K. (2015) · Journal of Genetics · doi:10.1007/s12041-015-0583-0 · Cited by 9
Siddique, H. R., Parray, A., Zhong, W., Karnes, R. J., Bergstralh, E. J., Koochekpour, S., Rhim, J. S., Konety, B. R., & Saleem, M. (2013) · PLoS ONE · doi:10.1371/annotation/d612ee51-4c8e-4468-8373-3d4c503f0da5 · Cited by 6
Ubiquitin-specific peptidase 22 controls integrin-dependent cancer cell stemness and metastasisPreprint
Liu, K., Gao, Q., Jia, Y., Wei, J., Chaudhuri, S. M., Wang, S., Tang, A., Mani, N. L., Iyer, R., Cheng, Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2922367/v1 · Cited by 6
Murali, P., Kavitha, B., & Narasimhan, M. (2024) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_517_24 · Cited by 8
Mitotic Regulator Hec1 as a Potential Target for Cancer Therapy
Goldblatt, E. M., Lee, E., & Lee, W. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-397833-2.00004-2 · Cited by 7
Chen, D., Song, D., Ma, Y., Lu, W., Qiu, J., & Wang, Y. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12665 · Cited by 6
Tumor Suppressor Role and Clinical Significance of the FEV Gene in Prostate Cancer
Liang, Y., Liang, Y., Zou, Z., Zhuo, Y., Ye, J.-H., Zhu, X., Cai, Z., Lin, Z., Mo, R., Wu, S., et al. (2022) · Disease Markers · doi:10.1155/2022/8724035 · Cited by 5
“Various molecular markers have been identified by gene expression profiling, which include AMACR [10], BMI-1 [11], EZH2 [12], PCA3 [13], and TMPRSS2-ERG [14].”
BackgroundPleshkan, V. V., Zinovyeva, M. V., & Sverdlov, E. D. (2011) · Molecular Biology · doi:10.1134/s0026893311030149 · Cited by 7
“markers of stem cells, does not differ between metastases and primary tumors [151].”
BackgroundA Note on Controlling the Number of False Positives
Korn, E. L., & Freidlin, B. (2007) · Biometrics · doi:10.1111/j.1541-0420.2007.00881.x · Cited by 6
“An interesting gene found by the MPT-based procedure and not by the Bonferroni-type procedure is BUB1, whose gene expression has been previously associated with survival in breast cancer patients (Glinsky, Berezovska, and Glinskii, 2005).”
MethodAmna, T., Hassan, M. S., & Sheikh, F. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-5622-7_3 · Cited by 5
The Kinetochore as Target for Cancer Drug Development
Liu, S., & Yen, T. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-69076-6_15 · Cited by 5
Molecular Biology of Breast Cancer
Snoj, N., Dinh, P., Bedard, P. L., & Sotiriou, C. P. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374419-7.00025-1 · Cited by 7
Darwish, N. H. E., Glinsky, G. V., Sudha, T., & Mousa, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.793810 · Cited by 5
Self-citationMarqueurs pronostiques et prédictifs de réponse aux traitements des cancers du sein
de Crémoux, P. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1207 · Cited by 10
When should I start using a new biomarker: Focus on expression arrays?
Desmedt, C., & Sotiriou, C. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)70029-0 · Cited by 4
QUANTITATIVE MULTIGENE EXPRESSION PROFILING OF PRIMARY PROSTATE CANCER
Meye, A., Schmidt, U., Fuessel, S., Koch, R., Baretton, G. B., Froehner, M., & Wirth, M. P. (2006) · European Urology Supplements · doi:10.1016/s1569-9056(06)60117-6 · Cited by 5
Regulation of H2B Monoubiquitination Pathway in Breast cancer
Bedi, U. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4876 · Cited by 5
Regulation of Treg Functions by the Ubiquitin Pathway
Montauti, E. I., & Fang, D. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6407-9_3 · Cited by 5
Friebus‐Kardash, J., Christ, T. C., Dietlein, N., Elwy, A., Abdelrahman, H., Holnsteiner, L., Hu, Z., Rodewald, H.-R., & Lang, K. S. (2023) · Vaccines · doi:10.3390/vaccines11101563 · Cited by 4
“More recent studies have shown a correlation between the overexpression of Usp22 and poor survival rates, the occurrence of metastases, and resistance to therapy with frequent recurrence of various types of cancer [7,21–26].”
BackgroundSystematic review and integrated analysis of prognostic gene signatures for prostate cancer patients
An, Y., Lu, W., Li, S., Lu, X., Zhang, Y., Han, D., Su, D., Jia, J., Yuan, J., Zhao, B., et al. (2023) · Discover Oncology · doi:10.1007/s12672-023-00847-4 · Cited by 5
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
An, Q., Neil, T., Ge, L., Arismendi, G. R., Paleo, B. J., Esteban, J., Shon, D. J., Hong, E., Ahmed, M., & Martin, R. (2013) · InTech eBooks · doi:10.5772/52363 · Cited by 4
“, [97] analyzed a wide variety of cancers by using microarray technology and discovered that a series of 11 genes (GBX2, Ki67, CCNB1, BUB1, KNTC2, USP22, HCFC1, RNF2, ANK3, FGFR2, and CES1) had a unique pattern.”
BackgroundTargeting the molecular mechanisms of glioma stem cell resistance to chemotherapy
Fares, J., Kanojia, D., Cordero, Á., Ulasov, I. V., & Lesniak, M. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00014-2 · Cited by 6
Alterations of histone modifications in cancer
Saber-Ayad, M. M., Ramadan, W. S. H., & El‐Awady, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18661-5.00018-x · Cited by 7
Castro‐Garcia, P., Gil‐Gas, C., Honrubia‐Gómez, P., Álvarez‐Simón, C. B., Ferre‐Fernández, J., Sánchez‐Sánchez, F., Sánchez-Sánchez, J. L., Garcia-Bueno, J. M., Sabater, S., Aparicio, G., et al. (2013) · Journal of Analytical Oncology · doi:10.6000/1927-7229.2013.02.04.2 · Cited by 4
microRNA in the control of stem-like phenotype of cancer cells
Woźniak, M. (2013) · Open Life Sciences · doi:10.2478/s11535-013-0222-9 · Cited by 5
Evaluating the link between stem cells and breast cancer
Cariati, M. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.8.1313 · Cited by 4
Yu, Y., Tu, K., Zheng, S., Li, Y., Ding, G., Ping, J., Hao, P., & Li, Y. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-264 · Cited by 5
“The application of microarrays to identify gene expression signatures of human diseases has been widely accepted [1,2].”
BackgroundZhao, Q., Gui, T., Qian, Q., Li, L., & Shen, K. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s109443 · Cited by 4
“The BMI1-driven 11-gene signature protocol established by Glinsky et al inspired us to think that the combined measurement and analysis of relevant biomarkers might be a more reliable strategy for risk assessment.(12,30) Similarly, Benard et al showed that high expression of all four markers (BMI1, EZH2, SUZ12, and H3…”
BackgroundMethodPersonalized, Multivalent, and More Affordable: The Globalization of Vaccines
Debinski, W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1101 · Cited by 4
Factors predicting poor survival after resection of stage IA non–small cell lung cancer
Paleari, L., Russo, P., Cesario, A., & Granone, P. M. (2008) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.11.056 · Cited by 4
Gene expression profiling in acute myeloid leukemia.
Bullinger, L. (2006) · PubMed · Cited by 4
USP22 regulates APL differentiation via PML-RARα stabilization and IFN repression
Kowald, L., Roedig, J., Karlowitz, R., Wagner, K., Smith, S. M., Juretschke, T., Beli, P., Müller, S. P., & van Wijk, S. J. L. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01894-8 · Cited by 6
“USP22 is highly expressed in several cancer types and USP22 abundance is linked to disease severity by promoting oncogenic gene expression, aberrant cell cycle regulation and cancer cell proliferation [9 – 11].”
Identification and evaluation of network modules for the prognosis of basal-like breast cancer
Hallett, R. M., Cockburn, J., Li, B., Dvorkin‐Gheva, A., Hassell, J. A., & Bane, A. L. (2015) · Oncotarget · doi:10.18632/oncotarget.4034 · Cited by 5
“To this end we calculated and compared P-value scores for the Genomic Grade Index [5], NKI-70 signature [31], Oncotype DX® score [3], CSR/Wound response signature [6], MS-14 signature [32], Glinsky stemness signature [33], Network module 2 [26] and the meta-PCNA signature described in Venet et al.”
Hepatocellular carcinoma reduces ATXN7L3 to evade estrogen-dependent growth suppression
Bean, J., & Mohan, R. D. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103179 · Cited by 3
“Overexpression of USP22 is associated with increased tumor growth, metastasis, and risk of death from cancer [8].”
BackgroundCHFR‑mediated epithelial‑to‑mesenchymal transition promotes metastasis in human breast cancer cells
Jiang, G., Fang, H., Xi, S., Chen, X., & Cao, F. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12090 · Cited by 5
Godugu, K., Karakus, O. O., Fujioka, K., Glinsky, G. V., & Mousa, S. A. (2022) · Journal of Cancer · doi:10.7150/jca.72522 · Cited by 3
“Overall, the workflow of the microarray analyses was modeled based on previously published contributions [15-17].”
MethodSelf-citationJiang, W., Yu, Y., Bhandari, A., Hirachan, S., Dong, X., Huang, X., Qu, J., & Chen, C. (2023) · Environmental Toxicology · doi:10.1002/tox.23812 · Cited by 3
“identified BUB1 as a gene whose up-regulated expression is associated with a bad prognosis.(15,16) As a result, it is possible to assume that tumorigenesis and BUB1 up-regulation are related in some way.”
BackgroundAo, N., Wang, L., & Liu, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139458 · Cited by 3
“5,6 Its expression correlates with a stem cell-like expression profile and appears to be driven by the BMI-1 oncogene.”
BackgroundGene signatures for risk-adapted treatment of bladder cancer
Orntoft, T. F., & Dyrskjøt, L. (2008) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/03008880802283730 · Cited by 3
“Recently, general ‘‘metastasis signatures’’ for solid tumours have been developed [38,39], but still lack validation in large-scale studies.”
BackgroundGene-Expression Microarrays Provide New Prognostic and Predictive Tests for Breast Cancer
Gong, Y., Symmans, W. F., & Pusztai, L. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.10.1359 · Cited by 4
Treatment of malignant pleural mesothelioma: current status and future directions
Zucali, P. A., Sanctis, R. D., Vincenzo, F. D., Simonelli, M., Lorenzi, E., Perrino, M., & Santoro, A. (2011) · Clinical Investigation · doi:10.4155/cli.11.72 · Cited by 3
Treatment tailoring based on molecular characterizations
Dinh, P., & Sotiriou, C. P. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn472 · Cited by 3
“Other prognostic signatures derived from the bottom-up approach include the wound response signature [26], mutant/ wild p53 signature [27], invasive gene signature (IGS) [28] and the cancer stem cell signature [29].”
BackgroundRosenblatt, M. (2012) · PubMed Central · Cited by 3
Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
Muselli, F., Mourgues, L., Morcos, R., Rochet, N., Nebout, M., Guerci‐Bresler, A., Faller, D. V., William, R., Mhaidly, R., Verhoeyen, E., et al. (2021) · Cancers · doi:10.3390/cancers13071693 · Cited by 3
“It regulates oncogenic phenotypes and promotes CSCs and therapy resistance in cancer cells [31,32].”
BackgroundClavicular Metastasis as an Initial Presentation of Papillary Thyroid Cancer
Fung, R. K., Fasen, M., Warda, F., Natter, P., Nedrud, S. M., Fernandes, R., Alkhasawneh, A., & Gandhi, G. Y. (2021) · Case Reports in Endocrinology · doi:10.1155/2021/6662071 · Cited by 3
“Some studies have shown that bone Case Reports in Endocrinology involvement is more frequent in well-differentiated thyroid cancer than moderately or poorly differentiated thyroid cancer, but this is not conclusive [13, 14].”
BackgroundRoad for Understanding Cancer Stem Cells: Model Cell Lines
Serakıncı, N., & Erzık, C. (2007) · Regenerative Medicine · doi:10.2217/17460751.2.6.957 · Cited by 3
Michael, J., Li, E. V., Huang, M., Handa, N., Kundu, N., Ho, A. Y., Patel, H. D., Proudfoot, J. A., Kumar, S. K. S., Schaeffer, E. M., et al. (2025) · The Prostate · doi:10.1002/pros.24924 · Cited by 2
Mythri, C., Jorvekar, S. B., Suraj, N., Pruthiviraj, N., Borkar, R. M., & Selvaraju, S. (2025) · Molecular Omics · doi:10.1039/d5mo00039d · Cited by 2
USP22 in human cancers: mechanistic insights and inhibitor development
Zhou, B., Lin, Z., Guo, Y., Xin, W., Ding, J., Tang, W., & Zhang, H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118865 · Cited by 4
Gao, X., Dan, Q., Zhang, C., Ding, R., Gao, E., Luo, H., Liu, W., & Lu, C. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.168917 · Cited by 2
Androgen receptor and osteoglycin gene expression predicting prognosis of metastatic prostate cancer
Kameda, T., Sugihara, T., Obinata, D., Oshima, M., Yamada, Y., Kimura, N., Takayama, K., Inoue, S., Takahashi, S., & Fujimura, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-74443-z · Cited by 2
“Several groups have attempted to develop tumor-derived RNA expression markers to enhance the predictive power of clinical variables [5–7].”
Breast cancer stem cells: A fallow research ground in Africa
Gyan, E., Fondjo, L. A., Owiredu, W. K. B. A., Jackson, A., & Green, A. R. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153118 · Cited by 2
Hec1/Nek2 Mitotic Pathway Inhibitor INH1 Inhibits the Cell Kinetic Parameters of A549 and HeLa Cells
Çeti̇n, İ. (2021) · Brazilian Archives of Biology and Technology · doi:10.1590/1678-4324-2021210233 · Cited by 2
“Upregulation and expression of HEC1 in cells has been associated with tumor grade and prognosis [14, 15].”
Biomarkers for Breast Cancer: Towards the Proposition of Clinically Relevant Tools
Daidone, M. G., Cappelletti, V., Paradiso, A., Gion, M., Harbeck, N., Sweep, F. C. G. J., & Schmitt, M. (2007) · Springer eBooks · doi:10.1007/978-3-540-36781-9_3 · Cited by 2
Cancer stem cells and bone metastasis
Strewler, G. J. (2008) · IBMS BoneKEy · doi:10.1138/20080335 · Cited by 2
Cancer Stem Cells: Biology and Potential Therapeutic Applications
Mangoni, M., Sottili, M., Loi, M., Gerini, C., Meattini, I., & Livi, L. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_8 · Cited by 2
Preventative and therapeutic strategies for cancer stem cells
Sell, S., & Glinsky, G. V. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511605536.006 · Cited by 6
Self-citationMadrid, F. F., Chen, W., Tang, N., Zhang, X., Dong, J., Sagar, H., & Abrams, J. (2010) · The Open Biomarkers Journal · doi:10.2174/1875318301003010013 · Cited by 2
“to represent a subset of highly malignant cancers with poor prognosis, including lung, prostate and breast cancer [22].”
BackgroundCell Origin of Tumors and the Persistence of Cancer Propagating Cells in Tumor Lesions
Aldinucci, D., & Perris, R. (2008) · The Open Pathology Journal · doi:10.2174/1874375700802010006 · Cited by 2
“Similarly, a stem cell-like 11-gene profile down-stream of Bmi-1 proposes a signature predictive of a short interval to disease recurrence, distant metastases, and death after therapy in patients affected by 11 different types of tumors [49].”
BackgroundHassan, M., El‐Khattouti, A., Haïkel, Y., Institut National de la Santé et de la Recherche Médicale, U. 9., & Megahed, M. (2014) · International Journal of Stem Cell Research and Transplantation · doi:10.19070/2328-3548-1400013 · Cited by 1
“This conserved Bmi-1-driven pathway correlated with earlier recurrence, distant metastases and death in 1153 cancer patients based on the analysis of 11 genes [118].”
BackgroundThe role of the cancer stem cell marker USP22 in tumors
(2016) · Stem Cell and Translational Investigation · doi:10.14800/scti.1219 · Cited by 2
“USP22 is one of these death-from-cancer signature genes [3] .”
BackgroundStemness Markers in Ovarian Cancer: Nature and Implications
hafez, A. A. E. (2014) · Journal of Cytology & Histology · doi:10.4172/2157-7099.1000e112 · Cited by 2
“ALDH1A1 was associated with chemoresistance in the ovarian cancer [14], and the presence of dual CD133/ALDH coexpressing cells in debulked primary tumor specimens correlated with reduced disease-free and overall survival in ovarian cancer patients [19], and evidenced superior tumor initiating capability in ovarian can…”
BackgroundReview Stem cells in human breast cancer
Oliveira, L. R., Jeffrey, S. S., & Ribeiro‐Silva, A. (2010) · Cited by 2
Mayburd, A. L., & Baranova, A. V. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7027-8_17 · Cited by 3
Liao, Y., Liang, X., Liang, W., Li, Z., Wang, Y., Wang, L., Zhen, S., Tang, B., & Wang, Z. (2019) · Oncology Letters · doi:10.3892/ol.2019.10154 · Cited by 4
SCARs: endogenous human stem cell-associated retroviruses and therapy-resistant malignant tumorsPreprint
Glinsky, G. V. (2015) · arXiv (Cornell University) · doi:10.48550/arxiv.1508.02022 · Cited by 2
“this true for cancer stem cells as well and activation of human stem cell-associated retroviruses (SCARs) occurs in malignant tumors? Activation of the stemness genomic networks in human malignant tumors was linked with the emergence of clinically-lethal death-from cancer phenotypes in cancer patients, which are consi…”
BackgroundSelf-citationRéponses aux thérapies ciblées : le cancer du poumon
Brambilla, E. M. (2009) · Annales de Pathologie · doi:10.1016/j.annpat.2009.07.033 · Cited by 2
Networks regulating ubiquitin and ubiquitin-like proteins promise new therapeutic targets
Marsh, D. J. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0585 · Cited by 3
“Numerous other DUBs have been associated with cancer, including USP22 that is part of an 11-gene ‘Death-fromCancer’ signature that predicts metastatic tumour behaviour, poor response to therapy and rapid recurrence across multiple different solid tumours (Glinsky et al. 2005).”
BackgroundCharacterisation of the long noncoding RNA GHSROS in prostate and breast cancer
Thomas, P. B. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122967 · Cited by 2
Patient, W. N. N., Shang, Z., Ntiak, A., & Apeku, E. (2023) · Research Square · doi:10.21203/rs.3.rs-3046481/v1 · Cited by 2
Fouad, M. (2018) · Advances in Cytology & Pathology · doi:10.15406/acp.2018.03.00058 · Cited by 1
“Median (Range) 13 (4-29) 14 (10-24) 13 (4-29) 15 (10-24) 13 (4-29) Table Continued.”
Alaei-Mahabadi, B., Elliott, K., & Larsson, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-74420-2 · Cited by 1
New sheriff in town: Cyclic peptide inhibitors of a DUB module
Alam, S., & Atanassov, B. S. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.04.001 · Cited by 1
Kuang, X., Salinger, A. P., Benavides, F. J., Muller, W. J., Dent, S., & Koutelou, E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0290837 · Cited by 2
Chaithra, N., Jain, A. S., Sahana, C., Shreevatsa, B., Rajendrasozhan, S., Dharmashekar, C., Suresh, K. P., Patil, S. S., Singh, P. P., Vishwanath, P., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1298786 · Cited by 1
“Carcinoma, sarcoma, leukemia, lymphoma, and myeloma are types of cancer (3).”
BackgroundTargeting deubiquitinating enzymes in cancer: navigating context-dependence for precision medicine
Khamjan, N. A. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2025-0359 · Cited by 1
“While it is frequently described as an oncogene and is a component of an “ 11-gene death-from-cancer ” signature via its stabilization of c-Myc, more recent evidence points to a more complex role [48, 68].”
Insights into the structure and evolution of the human SAGA complex by affinity-ligand purification
Damilot, M., Schoeps, T., Tora, L., Schultz, P., Lebeau, L., Pápai, G., & Shem, A. B. (2026) · Science Advances · doi:10.1126/sciadv.aec8104 · Cited by 1
Gao, Y., Zhang, K., Li, W., Liu, J., Kwon, D., Gu, L., Li, A., Yin, H. H., Kowolik, C. M., Raul, M. C., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125561 · Cited by 2
“Consistent with these functions, USP22 overexpression promotes chemoresistance, cancer stemness, angiogenesis, and metabolic reprogramming across multiple cancers [9,19–23].”
Bioinformatics in Personalized Cancer Care
Buetow, K. H. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00068-9 · Cited by 1
Genetic and Signaling Pathway Regulations of Tumor-Initiating Cells of the Prostate
Mulholland, D. J., & Wu, H. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6498-3_5 · Cited by 1
Stem Cells and Prostate Cancer
Çetintaş, V. B., Tezcanl, B., & Kosov, B. (2013) · InTech eBooks · doi:10.5772/52289 · Cited by 1
Biomarkers for Huntington’s Disease
Kobal, J., Lovrei, L., & Peterli, B. (2012) · InTech eBooks · doi:10.5772/32757 · Cited by 2
“In cancer therapy, several studies have been published where expression signatures indicated the response to certain treatment (Glinsky et al 2005, Rosenwald et al 2002).”
BackgroundRich, J. N. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-553-8_29 · Cited by 1
Strategies to potentiate immune response after photodynamic therapy
Hamblin, M. R. (2015) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2081029 · Cited by 1
“Moreover, some studies suggest that epigenetic processes are related to the metastatic characteristic of some tumors compared to others [77-80].”
Enzymatic assays for assessing histone deubiquitylation activity
Sussman, R. T., Zhang, X., & McMahon, S. B. (2011) · Methods · doi:10.1016/j.ymeth.2011.04.001 · Cited by 1
Genomic tracing of the elusive liver cancer ancestor
Cornellà, H., & Villanueva, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.016 · Cited by 1
Transcriptional Profiling of Prostate Cancer: Biomarker Identification and Clinical Applications
Clegg, N. J., & Nelson, P. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-281-0_17 · Cited by 1
“Using a mouse/human translational comparative genomics approach Glinsky et al. ( 34 ) identified an 11-gene expression signature that predicted outcome in patients with 11 distinct types of cancer, including prostate cancer.”
MethodInfluentialTravis, W. D. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283030.74046.34 · Cited by 1
The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities
Wu, B. J., & Chung, L. W. K. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-34211-5_9 · Cited by 1
Prediction of Radiation Response
Begg, A. C. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5897-7.00005-6 · Cited by 1
Cofré, J., & Abdelhay, E. (2017) · Hematology and Leukemia · doi:10.7243/2052-434x-5-1 · Cited by 1
“Consistent with the rupture of regulatory loop equilibrium the PcG proteins overexpression seems to be a trademark for some types of tumors [5,6,9,10,20].”
BackgroundNeurobiosensors: novel approaches towards early diagnostics of neurodegenerative disorders
Parihar, A., Sharma, P., Choudhary, N. K., & Khan, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95539-3.00007-7 · Cited by 2
Cancer Classification in Imbalance Data Using Double Filtering Approach
Mujhid, A., Tedjasulaksana, J. J., Masaling, N. A. P., & Girsang, A. S. (2023) · International Conference on Information Technology, Information Systems and Electrical Engineering (ICITISEE) · doi:10.1109/icitisee58992.2023.10404213 · Cited by 1
“The causes of cancer are multifactorial and may involve genetic mutations, environmental factors (such as exposure to carcinogens), lifestyle choices (such as tobacco use, diet, and physical activity), and certain infections[4].”
BackgroundAdditional considerations in cancer cell radioresistance, integrin αvβ3 and thyroid hormones
Glinsky, G. V., Hercbergs, A. A., Mousa, S. A., Lin, H., & Davis, P. J. (2024) · Endocrine Research · doi:10.1080/07435800.2024.2361152 · Cited by 1
Self-citationPatient, W. N. N., Zhong-hua, S., Ntiak, A., & Apeku, E. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.126015 · Cited by 2
“Moreover, overexpression of CCNB1 was also said to be associated with cancer metastasis and to have a poor outcome [16] [17] [18] [19].”
BackgroundTargeting Brain Cancer Stem Cells in the Clinic
Liu, G., Black, K. L., & Yu, J. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-933-8_22 · Cited by 1
Metadata
- Authors
- Glinsky, G. V., Berezovska, O., & Glinskii, A. B.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Corresponding author
- Glinsky, Gennadi V.
- ORCID
- Glinsky, Gennadi V.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1503-1521
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1136989
- OpenAlex
- W2166666333
- Cited by
- 916
- References
- 68
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 22 · 2023: 30 · 2022: 25 · 2021: 29 · 2020: 25 · 2019: 27 · 2018: 38 · 2017: 35 · 2016: 30 · 2015: 50 · 2014: 57 · 2013: 51 · 2012: 60
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (5R01CA89827, R01CA089827)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- cancer stem cells, BMI1, stem cell self-renewal, gene expression signatures, metastasis, treatment failure, prognosis, distant metastasis, recurrence, epithelial malignancies, hematologic malignancies, multi-cancer analysis
- MeSH terms
- Animals, Female, Humans, Male, Mice, Transgenic, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Repressor Proteins, Biomarkers, Tumor, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Polycomb Repressive Complex 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.